Cargando…

SAMHD1 is a barrier to antimetabolite-based cancer therapies

The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rudd, Sean G., Schaller, Torsten, Herold, Nikolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383367/ https://www.ncbi.nlm.nih.gov/pubmed/28401188 http://dx.doi.org/10.1080/23723556.2017.1287554

Ejemplares similares

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites
por: Herold, Nikolas, et al.
Publicado: (2017)

PNP inhibitors selectively kill cancer cells lacking SAMHD1
por: Davenne, Tamara, et al.
Publicado: (2020)

New control of the senescence barrier in breast cancer
por: Costa, Tânia D. F., et al.
Publicado: (2020)

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy
por: Mikucki, Maryann E., et al.
Publicado: (2016)

The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration
por: Watt, Jennifer, et al.
Publicado: (2013)

BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
por: Cirillo, Luca, et al.
Publicado: (2016)

BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
por: Sancho, Mónica, et al.
Publicado: (2021)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model
por: Lim, Joanne YH, et al.
Publicado: (2014)

Battling the two-headed dragon of prostate cancer targeted therapy
por: Wilkinson, Scott, et al.
Publicado: (2020)

DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy
por: Cheng, Xiang, et al.
Publicado: (2020)

Cancer testis antigens: A new paradigm for cancer therapy
por: Suri, Anil, et al.
Publicado: (2012)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

Tuning protein synthesis for cancer therapy
por: Knight, John R. P., et al.
Publicado: (2021)

Toward a rational design of combination therapy in cancer
por: Doucey, Marie-Agnès, et al.
Publicado: (2015)

Chemoimmunotherapy as long-term maintenance therapy for cancer
por: Egilmez, Nejat K., et al.
Publicado: (2012)

Trial watch: Immunostimulatory cytokines in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2014)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy
por: Konda, Prathyusha, et al.
Publicado: (2020)

How to develop better screens for anti-cancer therapies?
por: Hong, Michelle, et al.
Publicado: (2012)

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2014)

Sustaining the spindle assembly checkpoint to improve cancer therapy
por: Visconti, Roberta, et al.
Publicado: (2015)

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
por: Rassidakis, George Z., et al.
Publicado: (2018)

Local immunomodulation for cancer therapy: Providing treatment where needed
por: Fransen, Marieke F, et al.
Publicado: (2013)

Application of iPS cell-derived macrophages to cancer therapy
por: Senju, Satoru, et al.
Publicado: (2014)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy
por: Kao, Chiao-Jung, et al.
Publicado: (2013)

β-endorphin neuron transplantation: A possible novel therapy for cancer prevention
por: Zhang, Changqing, et al.
Publicado: (2012)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Crack the state of silence: Tune the depth of cellular quiescence for cancer therapy
por: Fujimaki, Kotaro, et al.
Publicado: (2017)

The double-edge sword effect of anti-CD73 cancer therapy
por: Stagg, John
Publicado: (2012)

Why should we need the gut microbiota to respond to cancer therapies?
por: Viaud, Sophie, et al.
Publicado: (2014)

ImmTACs: Novel bi-specific agents for targeted cancer therapy
por: Oates, Joanne, et al.
Publicado: (2013)

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers
por: Lebret, Thierry, et al.
Publicado: (2015)

Endogenous and exogenous glucocorticoids abolish the efficacy of immune-dependent cancer therapies
por: Ma, Yuting, et al.
Publicado: (2019)

Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective
por: Huang, Xing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dufllagnv5bq6k8h5pserphnct